Janssen Pharmaceuticals, Inc.
29 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 7 name spellings.
5
Ending by 2030
Jul 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 18 to 27, 2026 · next Dec 18
- 5 fees due Jan 18 to 30, 2027 · next Jan 18
- 2 fees due Feb 15, 2027
- 1 fee due Mar 15, 2027The maintenance fee for 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones (US 9,132,122) comes due Mar 15, 2027. Unpaid by Sep 15, 2027, it lapses early.
- 3 fees due Apr 3 to 24, 2027 · next Apr 3
- 1 fee due May 28, 2027The maintenance fee for Induce and enhance immune responses using recombinant replicon systems (US 11,826,416) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
- 2 fees due Jun 19, 2027
- 3 fees due Jul 7 to 26, 2027 · next Jul 7
- 2 fees due Aug 2 to 27, 2027 · next Aug 2
- 1 fee due Sep 5, 2027The maintenance fee for Grip Accessory for a Manual Injection Device (US 11,918,791) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.
- 1 fee due Nov 3, 2027The maintenance fee for Aza-Pyridone Compounds and Uses Thereof (US 9,328,119) comes due Nov 3, 2027. Unpaid by May 3, 2028, it lapses early.
Recent changes
- 3 of the patents on this record were granted since Aug 18, 2026
- 4 terms have ended since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,749,730 | High throughput screening assay for the TRPM5 ion channel In force · From the USPTO record | In force | From the USPTO record | |
| US 11,071,729 | 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones In force · From the USPTO record | In force | From the USPTO record | |
| US 9,132,122 | 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones In force · From the USPTO record | In force | From the USPTO record | |
| US 8,716,480 | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors In force · From the USPTO record | In force | From the USPTO record | |
| US 9,737,533 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders In force · From the USPTO record | In force | From the USPTO record | |
| US 8,937,060 | 1,2,4-Triazolo [4,3-a] Pyridine Derivatives and Their Use for the Treatment of Prevention of Neurological and Psychiatric Disorders In force · High confidence | In force | High confidence | |
| US 9,243,022 | Substituted Nucleosides, Nucleotides and Analogs Thereof In force · High confidence | In force | High confidence | |
| US 9,249,174 | Substituted Nucleosides, Nucleotides and Analogs Thereof In force · High confidence | In force | High confidence | |
| US 9,849,169 | MDR E. coli specific antibody In force · From the USPTO record | In force | From the USPTO record | |
| US 10,206,992 | MDR E. Coli Specific Antibody In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 101: 29 patents in force now held by others · 70 lapsed for an unpaid fee · 6 ended at full term · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
37 pending · 36 abandoned · 31 no status recorded